Programming the immune checkpoint to treat hematologic malignancies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programming the immune checkpoint to treat hematologic malignancies
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 7, Pages 755-770
Publisher
Informa UK Limited
Online
2016-04-13
DOI
10.1080/13543784.2016.1175433
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia
- (2015) Maciej Grzywnowicz et al. ACTA HAEMATOLOGICA
- Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma
- (2015) Semra Paydas et al. ANNALS OF HEMATOLOGY
- Immune checkpoint blockade in hematologic malignancies
- (2015) P. Armand BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Radiotherapy Complements Immune Checkpoint Blockade
- (2015) Shin Foong Ngiow et al. CANCER CELL
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
- (2015) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Friends Not Foes: CTLA-4 Blockade and mTOR Inhibition Cooperate during CD8+T Cell Priming To Promote Memory Formation and Metabolic Readiness
- (2015) Virginia A. Pedicord et al. JOURNAL OF IMMUNOLOGY
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Programmed cell death-1 inhibition in lymphoma
- (2015) Eliza A Hawkes et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
- (2015) F Castagnetti et al. LEUKEMIA
- Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration
- (2015) Lei Zhang et al. MEDICAL HYPOTHESES
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Programmed Cell Death Receptor Ligand 1 Modulates the Regulatory T Cells’ Capacity to Repress Shock/Sepsis–Induced Indirect Acute Lung Injury by Recruiting Phosphatase Src Homology Region 2 Domain-Containing Phosphatase 1
- (2015) Lunxian Tang et al. SHOCK
- Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody
- (2015) Lidia Ciszak et al. TUMOR BIOLOGY
- TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses
- (2015) Tomohisa Okamura et al. Nature Communications
- PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
- (2015) Y Kong et al. Blood Cancer Journal
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
- (2015) D. J. Chung et al. Cancer Immunology Research
- Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
- (2015) Andrea Gras Navarro et al. Frontiers in Immunology
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- (2014) R. Jitschin et al. BLOOD
- Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection
- (2014) Derek L. Clouthier et al. CYTOKINE & GROWTH FACTOR REVIEWS
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Use of CD137 ligand expression in the detection of small B-cell lymphomas involving the bone marrow
- (2014) Shuchun Zhao et al. HUMAN PATHOLOGY
- Regulation of T cell responses by the receptor molecule Tim-3
- (2014) Jacob V. Gorman et al. IMMUNOLOGIC RESEARCH
- Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma
- (2014) Kui Shin Voo et al. INTERNATIONAL JOURNAL OF CANCER
- Glucocorticoid-Induced TNF Receptor Expression by T Cells Is Reciprocally Regulated by NF- B and NFAT
- (2014) Y. Zhan et al. JOURNAL OF IMMUNOLOGY
- CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity
- (2014) E. M. Schmidt et al. JOURNAL OF IMMUNOLOGY
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
- (2014) Anas Younes et al. LANCET ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model
- (2014) Yuya Yoshimoto et al. PLoS One
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines
- (2013) J. Fourcade et al. CANCER RESEARCH
- Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells
- (2013) L. Wang et al. HAEMATOLOGICA
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification
- (2013) Céline Berthon et al. LEUKEMIA RESEARCH
- Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor
- (2013) A J Robert McGray et al. MOLECULAR THERAPY
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
- (2013) W. L. Redmond et al. Cancer Immunology Research
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- Cutting Edge: 4-1BB Controls Regulatory Activity in Dendritic Cells through Promoting Optimal Expression of Retinal Dehydrogenase
- (2012) S.-W. Lee et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire
- (2012) J. Verhagen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions
- (2012) Hans Klingemann et al. TRANSFUSION
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis
- (2011) G. Thangavelu et al. JOURNAL OF AUTOIMMUNITY
- Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)
- (2011) C Buechele et al. LEUKEMIA
- Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
- (2010) Soranobu Ninomiya et al. ANNALS OF HEMATOLOGY
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
- (2010) Jia Ruan et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2010) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
- (2009) R. A. Wilcox et al. BLOOD
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
- (2008) Luc Xerri et al. HUMAN PATHOLOGY
- NK cells and cancer immunosurveillance
- (2008) I Waldhauer et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search